Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca is seeking approval from the FDA for a new indication for its drug Seroquel for the treatment of patients with depressive episodes associated with bipolar disorder.
Subscribe to our email newsletter
The drug is currently approved for the treatment of acute manic episodes associated with bipolar disorder and the treatment of schizophrenia. Bipolar disorder consists of recurring episodes of mania and depression.
“If Seroquel receives approval from the FDA to treat bipolar depression, it would be the only single agent indicated to treat both the depressive and manic episodes associated with bipolar disorder,” said Dr Wayne Macfadden, US medical director for Seroquel.
The submission is based on results from two clinical studies. In both studies, patients receiving Seroquel, as compared to those receiving placebo, showed a statistically significant decrease in depression scores at week one, and scores continued to decrease throughout the eight-week study. More than half of the Seroquel treated patients in each trial met the criteria for remission.